Dr. Stephan Polterauer, MD

Claim this profile

AKH - Medizinische Universitat Wien

Studies Endometrial Cancer

Studies Cervical Cancer

4 reported clinical trials

11 drugs studied

Area of expertise

1Endometrial Cancer

Stephan Polterauer, MD has run 2 trials for Endometrial Cancer. Some of their research focus areas include:

TP53 positive

Stage IV

2Cervical Cancer

Stephan Polterauer, MD has run 1 trial for Cervical Cancer. Some of their research focus areas include:

Stage IV

Clinical Trials Stephan Polterauer, MD is currently running

More about Stephan Polterauer, MD

Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Stephan Polterauer, MD has experience with

Gemcitabine
Irinotecan
Pemetrexed
Tisotumab Vedotin
Topotecan
Vinorelbine

Breakdown of trials Stephan Polterauer, MD has run

Endometrial Cancer

Cervical Cancer

Tisotumab Vedotin vs Chemotherapy for Cervical Cancer

Relapse

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Ovarian Cancer

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Stomach Cancer

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

What does Stephan Polterauer, MD specialize in?

Stephan Polterauer, MD focuses on Endometrial Cancer and Cervical Cancer. In particular, much of their work with Endometrial Cancer has involved TP53 positive patients, or patients who are Stage IV.

Is Stephan Polterauer, MD currently recruiting for clinical trials?

Yes, Stephan Polterauer, MD is currently recruiting for 1 clinical trial in Vienna Other. If you're interested in participating, you should apply.

Are there any treatments that Stephan Polterauer, MD has studied deeply?

Yes, Stephan Polterauer, MD has studied treatments such as Gemcitabine, Irinotecan, Pemetrexed.

What is the best way to schedule an appointment with Stephan Polterauer, MD?

Apply for one of the trials that Stephan Polterauer, MD is conducting.

What is the office address of Stephan Polterauer, MD?

The office of Stephan Polterauer, MD is located at: AKH - Medizinische Universitat Wien, Vienna, Other 1090 Austria. This is the address for their practice at the AKH - Medizinische Universitat Wien.

Is there any support for travel costs?

The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.

Top trials Stephan Polterauer, MD is currently running

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

1045 Sansome St, Suite 321, San Francisco, CA

hello@withpower.com (415) 900-4227

Directories

Locations

Psychology Related

Treatments

Cities

···

Dr. Stephan Polterauer, MD

AKH - Medizinische Universitat Wien

Area of expertise

Clinical Trials Stephan Polterauer, MD is currently running

More about Stephan Polterauer, MD

Other Doctors you might be interested in

Frequently asked questions

Personalize Your Experience

Save Your Preferences

Understand How the Site Is Used

Dr. Stephan Polterauer, MD

AKH - Medizinische Universitat Wien

Area of expertise

Clinical Trials Stephan Polterauer, MD is currently running

Navtemadlin

for Endometrial Cancer

This trial tests navtemadlin to see if it can prevent endometrial cancer from returning in patients who responded well to chemotherapy. The study will check the safety and effectiveness of different doses of the drug.

More about Stephan Polterauer, MD

Other Doctors you might be interested in

Frequently asked questions